API | trilaciclib

trilaciclib Report issue

Small molecule Approved ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

AACT PubChem

Active Ingredient History

NOW

A CDK inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

g1t28 | trilaciclib

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Bone Marrow Diseases (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Healthy Volunteers (Phase 1)

Lung Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 4)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue